Actionable news
All posts from Actionable news
Actionable news in MRK: MERCK & CO. Inc,

Cancer Immunotherapy ETF Takes Curious Approach To Asset Allocation

The Loncar Cancer Immunotherapy ETF was launched recently with the goal of targeting companies actively engaged in the treatment of cancer through immunotherapy.

The fund's investment in both healthcare mega-caps and biotech small-caps provide very different exposure to immunotherapy treatments.

This fund looks more like a broader healthcare ETF than a pure play on cancer immunotherapy.

The ETF world is becoming increasingly niche oriented lately and another niche ETF - the Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) - recently joined the fray. Biotech has been a popular place to create a new product lately as ETFs targeting companies involved in genomics, drugs in late stage clinical trials and medical breakthroughs have all hit the market in the past 12 months.

According to the fund's fact sheet, the Cancer Immunotherapy ETF "is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in this approach." It charges an expense ratio of 0.79% and equal weights the portfolio among 30 holdings.

How it chooses those 30 holdings is...